Navigation Links
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
Date:8/4/2009

EXTON, Pa., Aug. 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Pharmaceutical Science and Clinical Pharmacology Advisory Committee supports the FDA's Office of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin(R) (vancomycin hydrochloride) capsules. Vancocin is used to treat severe, often life-threatening bacterial infections of the gastrointestinal (GI) tract, Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus. The draft guidelines, if approved, would allow generic manufacturers to use less rigorous standards, including in vitro rather than in vivo testing, for establishing BE rather than using comparative clinical trials. ViroPharma scientists and other leading experts voiced their concern that these new guidelines could jeopardize patient safety.

"We're appreciative that the FDA convened this advisory committee to provide a forum for open debate and discussion regarding a serious public health issue," said Vincent J. Milano, ViroPharma's president and chief executive officer. "While we're disappointed with the vote, we hope that the OGD will take every precaution to ensure that CDI patients will be treated with truly bioequivalent versions of vancomycin, given the life-threatening nature of the disease."

The Advisory Committee was asked if the proposed OGD guidelines and the use of in vitro dissolution methods are sufficient for establishing bioequivalence for generic vancomycin oral capsules. The Advisory Committee voted unanimously in favor of the proposed OGD recommendation to demonstrate bioequivalence through equivalent dissolution in media of pH 1.2, 4.5 and 6.8 for potential vancomycin HCl capsule
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
2. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
3. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
4. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
5. ViroPharma to Present at Two May Healthcare Conferences
6. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
7. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
8. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
9. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
10. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 In the key developed markets, ... 2013 and is set to decrease through 2020 at a ... growth is expected up to 2017 at a 2.6% CAGR ... be owing to the surging penetration of fixed-dose combination drugs ... Plus, Valturna, Benicar HCT, and Tekamlo), a hike in the ...
(Date:3/26/2015)... In preparation for the 2016 United States ... Samir Becic, has issued “report cards” for potential ... fitness, as well as their promotion of health and ... Ted Cruz, who has officially announced his candidacy for ... who have shown interest in running for office. This ...
(Date:3/26/2015)... With the rapidly growing healthcare market and consumers ... its not just doctors who are now purchasing medical ... a piece of the action. HealthSource Chiropractic ®, the ... franchises purchased by people with no health backgrounds to ... Chiropractic is an exploding $12.7 billion dollar market with ...
(Date:3/26/2015)... 26, 2015 The beauty industry united ... a man who revolutionized the business of beauty education. ... Passage; founder of Pivot Point International, Inc. Passage’s wife ... of Leo. Held at the Art Institute of Chicago, ... of industry and media leaders and served as the ...
(Date:3/26/2015)... LinkToBanking, a Preferred Partner Network for the cannabis ... of the Board and Robert Casares as Vice-Chairman ... combined knowledge and experience in regulatory compliance and ... Casares will provide exceptional guidance on how to ... About Tom Fleming, Mr. Fleming, CAMS, has over ...
Breaking Medicine News(10 mins):Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 2Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 3Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... team of researchers, including a number from the University of ... regions of the genome that contribute to the debilitating lung ... Their findings provide insight into the causes of the wide ... also points the way to new diagnostic markers and therapeutic ...
... , MONDAY, May 23 (HealthDay News) -- Cancer patients who ... greater sense of satisfaction about their treatment, a new study ... and accurate medical information built trust between patient and doctor. ... , the study analyzed 295 patients recently diagnosed with lymphoma, ...
... Monday, May 23, 2011 New findings out of Wake Forest ... in predicting early death in individuals with diabetes. ... Care . "People with diabetes are already at high risk ... W. Bowden, Ph.D., the director of the Center for Diabetes Research ...
... 22, 2011- Gothenburg, Sweden : The aldosterone antagonist ... new onset atrial fibrillation and flutter (AFF) in ... sub-analysis of the EMPHASIS-HF trial, presented at the ... Failure Association of the European Society of Cardiology ...
... Although chemotherapy is used to kill cancer cells, it ... such as bone marrow and blood cells, often limiting the ... Fred Hutchinson Cancer Research Center reported at today,s annual meeting ... Seattle that one possible approach to reduce this toxic effect ...
... , FRIDAY, May 20 (HealthDay News) -- The ... skin -- is significantly higher among overweight and obese kids, ... online in the Journal of Pediatrics , also found ... higher cholesterol levels, putting them at greater risk for heart ...
Cached Medicine News:Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Cancer Patients Benefit From Full Access to Medical Records 2Health News:Common test could help predict early death in diabetes, study shows 2Health News:Common test could help predict early death in diabetes, study shows 3Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 2Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 3Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted its first abbreviated ... Drug Administration (FDA) of 2015, which brings the Company,s ... FDA to twenty-three. Jason Grenfell-Gardner , ... 2, 2015, we committed to file at least twenty ...
(Date:3/26/2015)... 26, 2015  CNBC profiled MJ Freeway , a ... a series "How I Did It," which features companies with ... Road" released yesterday, illustrates how two tech entrepreneurs from ... providers to the marijuana industry. ... Co-Founders Amy Poinsett and Jessica Billingsley used their ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
... ... Fibrillation Patients, CARLSBAD, Calif., Jan. 16 Ablation ... U.S.,Investigational Device Exemption (IDE) clinical trial for interventional,treatment of chronic atrial ... proceed with the pivotal phase of the,study is based on the ...
... Jan. 16 Cerimon,Pharmaceuticals, Inc., announced today it ... studies of its once-,daily topical diclofenac sodium patch ... studies, designated the "SUPPORT" (Stop Underlying Pain with ... assess the,efficacy and safety of Cerimon,s patch compared ...
Cached Medicine Technology:FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 2Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 3
... IDT six-slice imaging system provides advanced ... innovations to maximize performance and minimize ... to delivering optimal clinical results, Mx8000 ... multislice CT today and the foundation ...
... The Mx8000 IDT 10 offers premium-level performance with ... on any other systems in the 8- and ... 0.4 second rotation time, and submillimeter isotropic imaging ... interface and a simple upgrade to a 16-slice ...
... for everyday, 1/2-second high-speed scanning, Aquilion ... image resolution with longer, faster helical ... imaging., An improved X-ray tube and ... this supercharged CT scanner, giving it ...
... to facilitate disc removal, endplate preparation and ... fusion. The TLIF instruments are very low ... for which they were primarily designed, however ... in PLIF and ALIF. Disc rongeurs: used ...
Medicine Products: